| Attributes | Values |
|---|
| rdf:type
| |
| rdfs:seeAlso
| |
| Description
| - Background: Despite the physiological sequestration of amyloid-beta (A beta) peptides by various carriers, interactions between peptides and protein tau appear to be pathological and involved in the development of Alzheimer's disease (AD). A recent study reported increased A beta-tau interactions in the neurons of AD patients. Objective: We investigated the possibility that levels of A beta-tau complexes in cerebrospinal fluid could be a prospective biomarker of AD, with greater sensitivity and specificity than A beta(1-42), tau, or phospho-tau individually. Methods: By means of ELISA, we estimated levels of the complexes in 161 people (non-demented controls, people with mild cognitive impairment (MCI), probable AD or other types of dementia). Results: We found significant reductions in levels in people with MCI due to AD (down to 84.5%) or with AD (down to 80.5%) but not in other types of dementia. The sensitivity of the new biomarker to AD was 68.6%, the specificity 73.3% (compared to controls) or 59.1-66.1% (compared to other types of dementia). No significant correlations were observed between the complexes and the remaining biomarkers or between those and Mini-Mental State Examination score. Conclusion: We suppose that attenuated levels of complexes in cerebrospinal fluid reflect the accumulation of A beta bound to tau in AD neurons and that changes start many years before symptom onset, analogously to those in A beta(1-42), tau, or phospho-tau. Unfortunately, these complexes are not a significantly better biomarker of AD than current biomarkers.
- Background: Despite the physiological sequestration of amyloid-beta (A beta) peptides by various carriers, interactions between peptides and protein tau appear to be pathological and involved in the development of Alzheimer's disease (AD). A recent study reported increased A beta-tau interactions in the neurons of AD patients. Objective: We investigated the possibility that levels of A beta-tau complexes in cerebrospinal fluid could be a prospective biomarker of AD, with greater sensitivity and specificity than A beta(1-42), tau, or phospho-tau individually. Methods: By means of ELISA, we estimated levels of the complexes in 161 people (non-demented controls, people with mild cognitive impairment (MCI), probable AD or other types of dementia). Results: We found significant reductions in levels in people with MCI due to AD (down to 84.5%) or with AD (down to 80.5%) but not in other types of dementia. The sensitivity of the new biomarker to AD was 68.6%, the specificity 73.3% (compared to controls) or 59.1-66.1% (compared to other types of dementia). No significant correlations were observed between the complexes and the remaining biomarkers or between those and Mini-Mental State Examination score. Conclusion: We suppose that attenuated levels of complexes in cerebrospinal fluid reflect the accumulation of A beta bound to tau in AD neurons and that changes start many years before symptom onset, analogously to those in A beta(1-42), tau, or phospho-tau. Unfortunately, these complexes are not a significantly better biomarker of AD than current biomarkers. (en)
|
| Title
| - Interactions between Amyloid-beta and Tau in Cerebrospinal Fluid of People with Mild Cognitive Impairment and Alzheimer's Disease
- Interactions between Amyloid-beta and Tau in Cerebrospinal Fluid of People with Mild Cognitive Impairment and Alzheimer's Disease (en)
|
| skos:prefLabel
| - Interactions between Amyloid-beta and Tau in Cerebrospinal Fluid of People with Mild Cognitive Impairment and Alzheimer's Disease
- Interactions between Amyloid-beta and Tau in Cerebrospinal Fluid of People with Mild Cognitive Impairment and Alzheimer's Disease (en)
|
| skos:notation
| - RIV/00216208:11130/14:10292989!RIV15-MSM-11130___
|
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| |
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/00216208:11130/14:10292989
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - tau protein; interactions; cerebrospinal fluid; biomarker; Amyloid-beta peptides (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| |
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| - Journal of Alzheimer's Disease
|
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...vavai/riv/projekt
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Hort, Jakub
- Laczó, Jan
- Vyhnálek, Martin
- Kolarova, Michaela
- Kristofikova, Zdena
- Ricny, Jan
- Ripova, Daniela
- Sirova, Jana
|
| http://linked.open...ain/vavai/riv/wos
| |
| issn
| |
| number of pages
| |
| http://bibframe.org/vocab/doi
| |
| http://localhost/t...ganizacniJednotka
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)